High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements,
so-called “double-hit” lymphomas (HGBL-DH), are aggressive lymphomas that form a …

The 2016 revision of the World Health Organization (WHO) classification for lymphoma has
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes.
Despite the majority of patients being cured with combination chemoimmunotherapy, up to …

MYC, as a powerful transcription factor, plays a vital role in various cancers. The clinical
significance of MYC alterations in diffuse large B-cell lymphoma (DLBCL) has been …

Genomic alterations and protein expression levels have been established as prognostic
factors for survival in patients with diffuse large B‐cell lymphoma (DLBCL). In particular …

Abstract The 2016 World Health Organization classification recognized “high-grade B-cell
lymphoma with MYC and BCL2 and/or BCL6 rearrangements”(double/triple-hit lymphoma …

It has been suggested that mean platelet volume (MPV) is associated with the risk of venous
thromboembolism (VTE) and increased mortality in patients with cancer. We evaluated the …

Introduction: Diffuse large B-cell lymphoma (DLBCL) is a molecularly heterogeneous
disease defined by different cellular origins and mechanisms of oncogenic activation …

Recent advances in interventional radiology have resulted in the utilization of small lymph
node biopsies, including fine-needle aspiration (FNA) and core needle biopsy (CNB) as an …

Background There are no immunophenotypic guidelines for the investigation of MYC‐
rearranged lymphomas. We aimed to identify simple immunophenotypic features that would …